ReviewNeuropsychiatric disease and treatment2017
Complexity and wide range of neuromyelitis optica spectrum disorders: more than typical manifestations.
Review in Neuropsychiatric disease and treatment, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 22 citations in OpenAlex.
- The role of neuroimmunology subspecialty in disease management of patients with neuromyelitis optica spectrum disorder.Orphanet journal of rare diseases · 2026Article
- Risk of Peripheral Artery Disease and Venous Thromboembolism in Patients with Neuromyelitis Optic Spectrum Disorder: A Nationwide Population-Based Cohort Study.International journal of medical sciences · 2026Article
- Intractable Vomiting as an Initial and Evasive Presentation of Neuromyelitis Optica Spectrum Disorder.Cureus · 2025Article
- Article
- [Predictors of disability in a cohort with neuromyelitis optica spectrum].Revista de neurologia · 2022Article
- MR imaging findings in primary spinal cord glioblastoma.Radiology case reports · 2021Article
- New Therapeutic Landscape in Neuromyelitis Optica.Current treatment options in neurology · 2021Review
- Cognitive impairment in NMOSD-More questions than answers.Brain and behavior · 2020Review
- Paroxysmal Symptoms in Multiple Sclerosis-A Review of the Literature.Journal of clinical medicine · 2020Review
- Transitional B cells involved in autoimmunity and their impact on neuroimmunological diseases.Journal of translational medicine · 2020Review
- Late Onset of Neuromyelitis Optica Spectrum Disorders.Neurology and therapy · 2019Article
- Article
- Neuromyelitis optica spectrum disorder with increased aquaporin-4 microparticles prior to autoantibodies in cerebrospinal fluid: a case report.Journal of medical case reports · 2019Article
- Neuromyelitis optica spectrum disorder presenting in an octogenarian.BMJ case reports · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neuromyelitis optica (NMO), considered to be mediated by autoantibodies, often cause severely disabling disorders of the central nervous system, and predominantly cause optic nerve damage and longitudinally extensive transverse myelitis. Remarkable progress has been made in deciphering NMO pathogenesis during the past decade. In 2015, the International Panel for NMO Diagnosis proposed the unifying term "NMO spectrum disorders" (NMOSD) and the updated NMOSD criteria reflects a wide range of disease and maintains reasonable specificity. Moreover, cumulative findings have indicated that NMOSD are frequently associated with multiple autoimmune diseases, thereby presenting complex clinical symptoms that make this disease more difficult to recognize. Notably, most neurologists do not heed these symptoms or comorbid conditions in patients with NMOSD. Whereas previous reviews have focused on pathogenesis, treatment, and prognosis in NMOSD, we summarize the present knowledge with particular emphasis on atypical manifestations and autoimmune comorbidities in patients with NMOSD. Furthermore, we emphasized the identification of these atypical characteristics to enable a broader and better understanding of NMOSD, and improve early accurate diagnosis and therapeutic decision making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.